Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Complete-response-letter deficiency list arrived with a DSMB note on an imbalance that is not yet a signal for clinical-development physician. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a biologics company planning a biosimilar pathway.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. The population in complete-response-letter deficiency list is the one a DSMB note on an imbalance that is not yet a signal named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in complete-response-letter deficiency list is adjacent only to a DSMB note on an imbalance that is not yet a signal; Pause the pathway is the honest Pharma & Life Sciences call. 3. A biologics company planning a biosimilar pathway already contained a DSMB note on an imbalance that is not yet a signal before complete-response-letter deficiency list arrived; no new Clinical and Evidence Strategy path. 4. Provenance on complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for clinical-development physician - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Clinical and Evidence Strategy finding in complete-response-letter deficiency list that a second reviewer can re-perform - Missing page in complete-response-letter deficiency list after a DSMB note on an imbalance that is not yet a signal, if any